Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations

Table 6 Independent factors for complete response at 12 mo of antiviral therapy in 232 patients who were treated with nucleos(t)ide analogues

	Complete response (n = 199)	Incomplete response (n = 33)	Univariate			Multivariate
			OR	95%CI	P value	OR	95%CI	P value
Gender (male)	130 (65.3%)	20 (60.6%)	1.225	(0.575-2.610)	0.600
Age, yr	47.3 ± 11.9	43.6 ± 10.9	1.028	(0.996-1.062)	0.087
HBeAg status (positive)	106 (53.3%)	30 (90.9%)	0.114	(0.034-0.386)	< 0.001	0.438	(0.086-2.226)	0.320
HBV-DNA, log10 IU/mL	5.97 ± 1.40	7.69 ± 1.13	0.402	(0.290-0.559)	< 0.001	0.185	(0.083-0.412)	< 0.001
qHBsAg, log10 IU/mL	3.46 ± 0.57	3.89 ± 0.74	0.270	(0.134-0.544)	< 0.001	1.492	(0.501-4.447)	0.473
AST, IU/L	94.6 ± 69.5	83.0 ± 47.2	1.003	(0.997-1.009)	0.361
ALT, IU/L	103.5 ± 92.7	91.6 ± 57.5	1.002	(0.997-1.006)	0.474
Total bilirubin, mg/dL	0.95 ± 0.57	0.76 ± 0.30	2.201	(0.964-5.024)	0.061
Albumin, g/dL	4.06 ± 0.53	4.14 ± 0.44	0.743	(0.351-1.573)	0.438
Prothrombin time, INR	1.05 ± 0.16	1.01 ± 0.10	8.323	(0.444-155.931)	0.156
Platelet count, × 103/mm3	164.6 ± 63.8	182.6 ± 53.0	0.995	(0.990-1.001)	0.128
Significant fibrosis	105 (52.8%)	13 (39.4%)	1.718	(0.810-3.644)	0.158
Liver cirrhosis	58 (29.1%)	6 (18.2%)	1.851	(0.726-4.720)	0.197
HCC	33 (16.6%)	3 (9.1%)	1.988	(0.573-6.899)	0.279
High genetic barrier	180 (90.5%)	12 (36.4%)	16.579	(7.069-38.882)	< 0.001	82.076	(14.945-450.760)	< 0.001
Pre-existing rtM204I	9 (4.5%)	8 (24.2%)	0.148	(0.052-0.419)	< 0.001	0.014	(0.002-0.096)	< 0.001

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; INR: International normalized ratio; qHBsAg: Quantitative hepatitis B surface antigen levels; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma.